28466-26-4

Basic information

• Product Name: 1H-PYRAZOL-4-YLAMINE
• Synonyms: 1H-Pyrazol-4-amine;4-Aminopyrazole 95%;AKOS PAO-0001;1H-PYRAZOL-4-YLAMINE;4-AMINOPYRAZOLE;4-AMINO-1H-PYRAZOLE;1H-Pyrazole-4-amine
• CAS NO: 28466-26-4
• Molecular Formula: C₃H₅N₃
• Molecular Weight: 83.0919
• EINECS: 1533716-785-6
• Product Categories: Pyrazole series;API intermediates
• Mol File: 28466-26-4.mol
• Article Data: 31

Chemical Properties

• Melting Point: 75-77°C
• Boiling Point: 142.17°C (rough estimate)
• Flash Point: 182.6°C
• Appearance: /
• Density: 1.0248 (rough estimate)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.5060 (estimate)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 17.70±0.50(Predicted)
• Sensitive: Hygroscopic
• CAS DataBase Reference: 1H-PYRAZOL-4-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-PYRAZOL-4-YLAMINE(28466-26-4)
• EPA Substance Registry System: 1H-PYRAZOL-4-YLAMINE(28466-26-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36/37
• WGK Germany: 3
• RTECS: UQ4993000
• HazardClass: IRRITANT
• Hazardous Substances Data: 28466-26-4(Hazardous Substances Data)

Usage

Description

1H-PYRAZOL-4-YLAMINE, also known as 4-Aminopyrazole, is an organic compound with the molecular formula C3H4N2. It is a versatile building block used in the synthesis of various pharmaceutical and biologically active compounds. Its chemical structure allows for the formation of different derivatives, making it a valuable component in the development of new drugs and therapies.

Uses

Used in Pharmaceutical Industry:
1H-PYRAZOL-4-YLAMINE is used as a building block for the preparation of pharmaceutical and biologically active compounds. Its unique chemical structure enables the development of a wide range of drugs with diverse therapeutic applications.
Used in Anticonvulsant Applications:
1H-PYRAZOL-4-YLAMINE has demonstrated anticonvulsant activity, making it a potential candidate for the treatment of epileptic seizures. Its ability to modulate neuronal activity and reduce seizure frequency can provide relief for patients suffering from epilepsy and other seizure disorders.

InChI:InChI=1/C3H5N3/c4-3-1-5-6-2-3/h1-2H,4H2,(H,5,6)

Upstream product

• 2075-46-9 4-nitro-1H-pyrazole 
• 116008-52-7 4-amino-1H-pyrazole-3-carboxylic acid 
• 7647-01-0 hydrogenchloride 
• 40769-81-1 pyrazolo<4,3-d>pyrimidine-5,7-(1H,4H,6H)-dione 
• 64-19-7 acetic acid 
• 23585-55-9 1-(4-pyrazolyl)ethanol 

Downstream Products

• 790697-57-3 sulfanilic acid-(1H-pyrazol-4-ylamide) 
• 3469-69-0 4-iodopyrazole 
• 91591-72-9 2,4-dichloro-6-methylpyridine-3-carbaldehyde 

Relevant articles and documents

Indazole, Pyrazole, and Oxazole Derivatives Targeting Nitric Oxide Synthases and Carbonic Anhydrases

Nitric oxide (NO) is an essential endogenous mediator with a physiological role in the central nervous system as neurotransmitter and neuromodulator. A growing number of studies have demonstrated that abnormal nitrergic signaling is a crucial event in the development of neurodegeneration. In particular, the uncontrolled production of NO by neuronal nitric oxide synthase (nNOS) is observed in several neurodegenerative diseases. Moreover, it is well recognized that specific isoforms of human carbonic anhydrase (hCA) physiologically modulate crucial pathways of signal processing and that low expression of CA affects cognition, leading to mental retardation, Alzheimer′s disease, and aging-related cognitive impairments. In light of this, dual agents that are able to target both NOS (inhibition) and CA (activation) could be useful drug candidates for the treatment of Alzheimer′s disease, aging, and other neurodegenerative diseases. In the present work, we show the design, synthesis, and in vitro biological evaluation of new nitrogen-based heterocyclic compounds. Among the tested molecules, 2-amino-3-(4-hydroxyphenyl)-N-(1H-indazol-5-yl)propanamide hydrochloride (10 b) was revealed to be a potent dual agent, able to act as a selective nNOS inhibitor and activator of the hCA I isoform.

INHIBITORS OF NECROPTOSIS

This invention relates to compounds of Formula (I) and salts, solvates, prodrugs, tautomers, N-oxides, stereoisomers, polymorphs and physiologically functional derivatives thereof. Also disclosed are methods of use of Formula (I), including in the inhibition of necroptosis and treatment of associated diseases, conditions and/or disorders.

Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors

Potent JNK3 isoform selective inhibitors were developed from a thiophenyl-pyrazolourea scaffold. Through structure activity relationship (SAR) studies utilizing enzymatic and cell-based assays, and in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies, potent and highly selective JNK3 inhibitors with oral bioavailability and brain penetrant capability were developed. Inhibitor 17 was a potent and isoform selective JNK3 inhibitor (IC50 = 35 nM), had significant inhibition to only JNK3 in a panel profiling of 374 wild-type kinases, had high potency in functional cell-based assays, had high stability in human liver microsome (t1/2 = 66 min) and a clean CYP-450 inhibition profile, and was orally bioavailable and brain penetrant. Moreover, cocrystal structures of compounds 17 and 27 in human JNK3 were solved at 1.84 ?, which showed that these JNK3 isoform selective inhibitors bound to the ATP pocket, had interactions in both hydrophobic pocket-I and hydrophobic pocket-II.